Equillium, Inc. (NASDAQ:EQ) Sees Significant Growth in Short Interest

Key Points

• Equillium, Inc. has experienced a significant increase in short interest, rising by 55.7% in September, reaching a total of 2,180,000 shares as of September 30th.
• The stock's current trading price is $1.29, with a market cap of $76.76 million and a consensus target price from analysts of $1.00.
• Equillium has received a "sell" rating from several research firms, indicating cautious outlooks from analysts regarding the company's performance moving forward.

Equillium, Inc. (NASDAQ:EQ - Get Free Report) saw a large growth in short interest in September. As of September 30th, there was short interest totaling 2,180,000 shares, a growth of 55.7% from the September 15th total of 1,400,000 shares. Based on an average daily volume of 7,820,000 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 7,820,000 shares, the short-interest ratio is presently 0.3 days.

Equillium Price Performance

Shares of EQ stock traded down $0.09 during midday trading on Wednesday, hitting $1.29. The company had a trading volume of 558,088 shares, compared to its average volume of 712,786. The stock has a market cap of $76.76 million, a price-to-earnings ratio of -2.30 and a beta of 1.53. The company's 50 day simple moving average is $1.54 and its 200 day simple moving average is $0.81. Equillium has a 52-week low of $0.27 and a 52-week high of $2.35.

Equillium (NASDAQ:EQ - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). Analysts anticipate that Equillium will post 0.14 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on EQ. Wall Street Zen raised Equillium to a "sell" rating in a research report on Friday, September 5th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Equillium in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Reduce" and a consensus target price of $1.00.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.